Drug General Information (ID: DDIV5PBYL9)
Drug Name			Cangrelor		Drug Info		Antithrombin Alfa		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Antiplatelet Agents				Recombinant Antithrombin

Mechanism of Cangrelor-Antithrombin Alfa Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Cangrelor				Antithrombin Alfa
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Anticoagulant
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Cangrelor and Antithrombin Alfa

Recommended Action
Management		Caution is recommended if cangrelor must be used in patients treated with other agents that alter hemostasis. Patients should be monitored for potentially increased bleeding complications.

References
1	Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Kengreal (cangrelor). The Medicines Company, Parsippany, NJ.